查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138301

全球抗癌药物市场-2022-2029

Global Cancer Treatment Drugs Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

政府和私人组织激活教育活动有望成为市场增长的驱动力

政府和私人组织的宣传计划有助于提高人们对诊断乳腺癌的认识并推动市场增长。对乳腺癌的认识很低，女性不愿谈论这种感染。许多政府发起的宣传计划有助于提高乳腺癌的诊断率。因此，早期诊断乳腺癌有助于提高治愈乳腺癌的机会。它还在预测期内为市场做出了贡献，因为治疗也可以更有效地提供。 NBCF（国家乳腺癌基金会）通过为美国和其他国家/地区的女性提供免费的乳房 X 光检查以及在国家乳房 X 线摄影计划下提供免费的乳腺癌教育来帮助世界各地的人们。该组织提供有关乳腺癌的重要资源，并通过对女性进行有关身体的教育，使她们能够控制自己的健康。包括个人培训课程、活动材料、在线培训模块等。 NCBF 与其他组织合作，为全国社区的女性提供乳腺癌教育和早期检测。

此外，癌症治疗研究和开发正在推动预测期内的市场增长。例如，2020 年 7 月，美国国家癌症研究所 (NCI) 资助了一项关于胰腺癌的高级研究计划，以促进我们对预防、检测和治疗的理解。胰腺癌比其他类型的癌症更难早期发现，并且通常在晚期被诊断出来。这项资助的胰腺癌研究包括测试早期和晚期胰腺癌的治疗方法。

全球肿瘤药物市场报告提供了大约 53 个市场数据表、47 个数字和 170 页的结构。

内容

第一章调查方法及范围

  • 调查方法
  • 市场范围

第 2 章主要趋势和发展

第 3 章执行摘要

  • 按药物类别划分的市场细分
  • 按指标划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
    • 约束因素
    • 商机
  • 影响分析

第五章行业分析

  • 波特五力分析
  • 价值链分析
  • 专利分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措

第 7 章按药物类别类型

  • 化疗
  • 靶向药物
  • 免疫疗法
  • 激素疗法

第 8 章适应症

  • 肺癌
  • 肝癌
  • 乳腺癌
  • 膀胱癌
  • 结肠癌
  • 前列腺癌
  • 胃癌

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 竞争场景
  • 竞争对手战略分析
  • 市场情况/份额分析
  • 併购分析

第 11 章公司简介

  • AbbVie, Inc
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene
  • CARsgen Therapeutics
  • CStone Pharmaceuticals Co., Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • JW Therapeutics
  • Legend Biotech Co.

第12章 DataM

简介目录
Product Code: DMHCIT2955

Market Overview

Cancer treatment drugs market was valued at USD 153.23 million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 10.6% during the forecast period (2022-2029).

The widespread prevalence of cancer leads to the rapid development of cancer treatment drugs. Various drugs have received regulatory approval from the USFDA (Food and Drug Administration) the cancer treatment. The leading pharmaceutical and biotechnology companies are developing their cancer research, considering the disease's rising global burden. The increasing cancer population worldwide due to the demand for cancer treatment drugs drives the market growth. Also, government involvement in raising awareness regarding cancer symptoms and their early diagnosis further contributes to the global market growth.

Market Dynamics: Increasing awareness programs by government and private organizations are expected to drive market growth.

Awareness programs by government and private organizations help to increase the awareness of the diagnosis in people for breast cancer which helps to drive market growth. There was less awareness about breast cancer; women hesitated to discuss that type of infection. The number of awareness programs by government initiatives helps to improve the breast cancer diagnosis rate; thus, early diagnosis of breast cancer helps to improve the chances of curing breast cancer. Also, the treatment can be more effective, which helps the market in the forecast period. The NBCF, National Breast Cancer Foundation, provides free mammograms to women across the US and other countries under the national mammography program and hands to help people worldwide by providing free breast cancer education. This organization provides important breast cancer resources and empowers women to control their health by educating them about their bodies. It includes personal training sessions, event material, and online training modules. The NCBF has partnered with other organizations to provide breast cancer education and early detection of breast cancer to women in the community across the country.

Moreover, the research and development in cancer treatment are boosting the market growth during the forecast period. For instance, in July 2020, National Cancer Institute (NCI) funded an advanced research program on pancreatic cancer to advance the understanding of prevention, detection, and treatment. Pancreatic cancer is hard to detect early compared to other types of cancers and is often diagnosed at an advanced stage. This funded research for pancreatic cancer includes testing treatments for early-stage pancreatic cancer and advanced pancreatic cancer treatments.

Market Segmentation: The chemotherapy segment accounted for the highest share in global cancer treatment drugs market.

Chemotherapy is the most widely used treatment for cancer which destroys and reduces cancer-growing cells. Systemic chemotherapy grows into the bloodstream to spread cancer cells throughout the body. Some of the most common ways of chemotherapy are an intravenous tube placed into a vein using a needle, an injection under the skin or into a muscle (intramuscular), and swallowing the drug and capsule. There are two types of chemotherapy such as adjuvant chemotherapy and neoadjuvant chemotherapy. The adjuvant chemotherapy destroys cancer cell spread and is not seen by imaging tests. The adjuvant chemotherapy reduces the cancer cells that form new tumors in the other place of the body.

Furthermore, breast cancer is expected to dominate the cancer treatment drugs market during the forecast period. The high prevalence of breast cancer in women worldwide drives the market. Most breast cancer begins either in the breast tissue made up of glands for milk production, called lobules or in the ducts that connect the lobules to the nipple. Breast cancer is the most common cancer in women in the developed and developing world. Breast cancer cases are increasing in developing countries due to reproductive, menstrual, and lifestyle changes. According to the World Health Organization report published in 2020, breast cancer has the largest number of new cases in 2020, estimated at 11.7% of the total new cases estimated during the year. Around 2.3 million new breast cancer cases were registered globally in 2020, with a mortality rate of about 685,000. Therefore, the expenditure on breast cancer therapies and medicines is increasing rapidly, which leads to the high diagnosis and treatment of breast cancer worldwide.

Geographical Penetration: North America is the dominating region during the forecast period.

North American region dominated the global cancer treatment drugs market and accounted for the largest market share. The well-developed healthcare infrastructure and key market players, such as Pfizer Inc., Merck & Co., Inc., and Johnson & Johnson Services, Inc., are factors driving the region's market growth. In North America, the US contributed the major share of around 85.0% in the regional market growth. Besides, Canada is expected to project a considerable CAGR in the regional market during the forecast period.

Additionally, high healthcare spending costs have been the primary reason for the growth of the market. As per the World Bank data, the US's disposable income was recorded as $10,350. Their national health expenditure was $3.3 trillion, promoting healthcare services usage and motivating the cancer treatment drugs market. The US Government has included various diagnostic tools to search for any indicative breast cancer symptoms to control and manage the disease. Besides, the public and private organizations have many reimbursement policies for lessening the financial burden arising due to the disease. Many organizations, such as the American Cancer Society, guide women who have breast cancer.

Competitive Landscape:

The cancer treatment drugs market is fragmented due to multiple companies' availability. Some of the major key players in the market are AbbVie, Inc., AstraZeneca PLC, Bayer AG, BeiGene, CARsgen Therapeutics, CStone Pharmaceuticals Co., Ltd. and GlaxoSmithKline PLC, among others. The key players are adopting various growth strategies, such as acquisitions, product launches, and collaborations, contributing to the growth of the cancer treatment drugs market globally. In July 2020, AstraZeneca and Merck & Co., Inc. announced that Lynparza (olaparib) had been approved in the European Union (EU) for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. This approval further provides the company with a significant opportunity to sustain a substantial European pancreatic cancer drugs market position. In June 2020, AbbVie collaborated with Jacobio Pharmaceuticals to develop and commercialize SHP2 inhibitors that act on an important node in cancer and immune cells. In January 2022, AbbVie Announced U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for the treatment of non-small cell lung cancer. In October 2021, US FDA approved Roche's Tecentriq as an adjuvant treatment for people with early non-small cell lung cancer. It is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting.

COVID-19 Impact: Negative impact on the global cancer treatment drugs market

The outbreak of the COVID-19 pandemic will harm the growth of the cancer treatment market in 2020. It has significantly affected oncology clinical research due to the increasing focus on clinical research for COVID-19 treatment. A large number of oncology trials were suspended due to the COVID-19 pandemic. It has also affected the enrollment of patients in oncology clinical trials in the US and Europe. Therefore, a modest decline in the cancer treatment market is estimated in 2020; however, the market is expected to regain growth in the third quarter of 2021

The global cancer treatment drugs market report would provide an access to approximately 53 market data tables, 47 figures and 170 pages

Table of Contents

Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Drug Class Type
  • 3.2. Market Snippet by Indication
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Drug Class Type

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Drug Class Type Segment
    • 7.1.2. Market attractiveness index, By Drug Class Type Segment
  • 7.2. Chemotherapy *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Targeted Therapy
  • 7.4. Immunotherapy
  • 7.5. Hormonal Therapy

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Indication Segment
    • 8.1.2. Market attractiveness index, By Indication Segment
  • 8.2. Lung Cancer *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Liver Cancer
  • 8.4. Breast Cancer
  • 8.5. Bladder Cancer
  • 8.6. Colorectal Cancer
  • 8.7. Prostate Cancer
  • 8.8. Stomach Cancer

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key region-specific dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Type.
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Type.
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Rest of South America
  • 9.4. Europe
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Type.
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. U.K.
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Italy
      • 9.4.5.6. Rest of Europe
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Type.
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Type.
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

10. Competitive Landscape

  • 10.1. Competitive scenario
  • 10.2. Competitor strategy analysis
  • 10.3. Market positioning/share analysis
  • 10.4. Mergers and acquisitions analysis

11. Company Profiles

  • 11.1. AbbVie, Inc*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. AstraZeneca PLC
  • 11.3. Bayer AG
  • 11.4. BeiGene
  • 11.5. CARsgen Therapeutics
  • 11.6. CStone Pharmaceuticals Co., Ltd.
  • 11.7. GlaxoSmithKline PLC
  • 11.8. Johnson & Johnson Services, Inc.
  • 11.9. JW Therapeutics
  • 11.10. Legend Biotech Co.
  • List not Exhaustive*

12. DataM

  • 12.1. Appendix
  • 12.2. About us and services
  • 12.3. Contact us